Clinical usefulness of dual-label Schilling test for pancreatic exocrine function.
The usefulness of the pancreatic dual-label Schilling test as an indirect test of pancreatic exocrine function was evaluated. This dual-label Schilling test was based on the difference of absorption for [58Co]cobalamin bound to hog R protein and [57Co]cobalamin bound to intrinsic factor. In this study, the test was performed in 7 normal subjects, 5 patients with pancreatectomy, 12 patients with chronic pancreatitis, 10 patients with suspicion of chronic pancreatitis, and 13 patients without chronic pancreatitis. The normal lower limit (mean -2 SD) of excretion ratio for [58Co]/[57Co] in 24-h urine was 0.68. Of the 26 patients on whom endoscopic retrograde pancreatography was performed, none of the 9 patients with normal pancreatogram, 4 of the 9 patients with mild to moderate pancreatitic changes in pancreatogram, and 7 of the 8 patients with advanced pancreatitic changes in pancreatogram showed a positive value lower than the ratio of 0.68 in this test. In 28 patients examined with the direct test of pancreatic secretory capacity, 2 of the 13 patients with normal function, 6 of the 9 patients with mild dysfunction, and 5 of the 6 patients with definite dysfunction were positive in this test. The results of the pancreatic dual-label Schilling test significantly correlated with those of a direct test of pancreatic secretory capacity and the findings of pancreatitic changes in pancreatogram (p less than 0.01, chi 2 test). The ratio for [58Co]/[57Co] correlated (r = 0.73) with the maximal bicarbonate concentration in duodenal juice of the direct test of pancreatic secretory capacity. The impairment of bicarbonate output by the pancreas may adversely affect the transfer of cobalamin from R protein to intrinsic factor. It suggested that the pancreatic dual-label Schilling test is useful for detecting not only patients with severe pancreatic insufficiency but also the relatively early stage of chronic pancreatitis with bicarbonate secretory dysfunction of the pancreas.
Chen
W L
WL
Department of Internal Medicine, Faculty of Medicine, Kyoto University, Japan.
Morishita
R
R
Eguchi
T
T
Kawai
T
T
Sakai
M
M
Tateishi
H
H
Uchino
H
H
D010129:4-Aminobenzoic Acid; D000328:Adult; D000818:Animals; D001639:Bicarbonates / Q000378:metabolism; D002760:Cholangiopancreatography, Endoscopic Retrograde; D002908:Chronic Disease; D003037:Cobalt Radioisotopes; D005260:Female; D006801:Humans; D006863:Hydrogen-Ion Concentration; D066298:In Vitro Techniques; D007437:Intrinsic Factor / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009687:Nuclear Proteins / Q000378:metabolism; D010179:Pancreas / Q000378:metabolism*; D010180:Pancreatectomy; D010186:Pancreatic Function Tests; D010195:Pancreatitis / Q000000981:diagnostic imaging / Q000503:physiopathology; D012546:Schilling Test; D013552:Swine; D014805:Vitamin B 12 / Q000378:metabolism; D062366:para-Aminobenzoates
D001639:Bicarbonates; D003037:Cobalt Radioisotopes; D009687:Nuclear Proteins; D062366:para-Aminobenzoates; C006717:bentiromide; D007437:Intrinsic Factor; D014805:Vitamin B 12; D010129:4-Aminobenzoic Acid